skip to content


4D pharma's Blautix achieves objective in clinical trial

23 May 2016 09:10

A phase 1 clinical trial of Blautix - 4D pharma's proprietary programme for the treatment of irritable bowel syndrome - has shown it is safe and well tolerated, achieving the primary objective.

The trial, involving 56 healthy volunteers and IBS patients, is providing clinical samples and data which will be used to support our understanding of the mechanism of action of Blautix and the effect of a live biotherapeutic on the microbiome.

In addition, the samples and data the trial is providing will be used to aid our development of a diagnostic for IBS. The company will report further on this over the coming weeks.

Chief executive Duncan Peyton said: "This is a further step towards taking our pipeline, and live biotherapeutics as a class, to market approval. We have shown Blautix to be safe and well tolerated, which we have always believed would be a keystone to the field of live biotherapeutics. In addition, this trial is providing patient samples that will give the Company a better understanding of what is happening in IBS patients undergoing treatment with Blautix. We believe that this will not only help with the design of the next clinical protocol, but also identify patients who will benefit most from treatment with our live biotherapeutic products."

At 9:10am: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was +9.5p at 840p

Story provided by

Related Company: DDDD

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.